Interstitial cystitis/bladder pain syndrome (ICBPS) is a disorder characterized by chronic pain, discomfort, and pressure in the pelvic region that often includes symptoms of urinary frequency and urgency. Janssen/bene-Arzneimittel’s Elmiron and Mylan’s intravesical dimethyl sulfoxide (RIMSO-50) are the only two pharmacological treatments approved for ICBPS, but other antihistamines, antidepressants, and antiepileptics may be used off-label to ameliorate symptoms. Because pharmacological treatments are usually only partially effective, they are often combined with nonpharmacological therapies in a trial-and-error approach. As such, substantial unmet need persists for more effective treatment options.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals for ICBPS?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for ICBPS?
  • What are the prevailing areas of unmet need and opportunity in ICBPS?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European urologists for a hypothetical new ICBPS drug?

PRODUCT DESCRIPTION

Unmet Need: Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 60 U.S. and 30 European urologists fielded in March 2018.

Key companies: bene-Arzneimittel, Janssen, Mylan, Pfizer.

Key drugs: Elmiron, amitriptyline, hydroxyzine, duloxetine, Lyrica, gabapentin, intravesical medications (lidocaine, heparin, dimethyl sulfoxide, hyaluronic acid, others).

Key metrics included:

  • Stated versus derived analysis of U.S. and European physician prescribing behavior.
  • Conjoint analysis with U.S. and European physicians, including market simulator.
  • Assessment of current drug performance against treatment drivers and goals.
  • Physician perceptions of unmet need in disease/subpopulation covered and related diseases/subpopulations.

Table of contents

  • Chronic Pain - Unmet Need - Detailed, Expanded Analysis: Interstitial Cystitis (US/EU)

Author(s): Natalie Taylor, PhD

Natalie Taylor, Ph.D. is a Principal Business Insights Analyst with the central nervous system/ophthalmology disorders team at Decision Resources Group. She has over ten years of experience authoring primary and market research reports for pharmaceutical industry clients across multiple psychiatry, pain, neurology, and ophthalmology therapy areas.

Prior to joining DRG, Dr. Taylor worked at QuintilesIMS as manager of the central nervous system portfolio of Disease Insights market forecasting offerings. She completed her Ph.D. in Physiology at Dartmouth College in Hanover, New Hampshire, where she studied the role of serotonergic neurons in the medullary raphe on modulating respiratory responses in mammals. She holds a B.S. in Biology from Dickinson College in Carlisle, Pennsylvania.


Related Reports

Chronic Pain - Landscape & Forecast - Disease Landscape & Forecast

A crowded generics market makes gaining a strong foothold in the treatment of chronic pain challenging for branded agents. The treatment of chronic pain involves the use of drugs from several drug...

View Details

Chronic Pain - Unmet Need - Detailed, Expanded Analysis: Complex Regional Pain Syndrome (US/FR/DEU/UK)

Complex regional pain syndrome (CRPS) is a debilitating pain condition characterized by persistent pain, typically in distal limbs, with intensit...

View Details

Chronic Pain - Unmet Need - Detailed, Expanded Analysis - Chronic Low Back Pain (US/EU)

Chronic low back pain (CLBP), defined as continuous low back pain lasting for at least three months, represents the largest segment of the chronic pain th...

View Details